SIENA Score and CVP/PCWP Predict Mid-Term Prognosis After LVAD Implantation: A Single-Center Study.

Area of Science:

• Cardiology
• Medical Devices
• Heart Failure Management

Background:

• Left ventricular assist device (LVAD) implantation is a key therapy for end-stage heart failure.
• Right ventricular failure (RVF) is a significant complication impacting LVAD patient outcomes.
• Predictive markers for RVF and adverse events post-LVAD are crucial for improving patient management.

Purpose of the Study:

• To validate echocardiographic and hemodynamic parameters for predicting RVF and adverse outcomes after LVAD implantation.
• To assess the efficacy of the SIENA protocol in identifying patients at low risk for RVF.
• To identify novel prognostic markers for mortality and hospitalization in LVAD recipients.

Main Methods:

• A cohort of 29 end-stage heart failure patients undergoing LVAD implantation was screened using the SIENA protocol and standard indications.
• Patients underwent right heart catheterization (RHC) and were followed for 1 year to monitor for RVF, mortality, and hospitalization.
• Various clinical, laboratory, echocardiographic, and RHC parameters were analyzed for their association with adverse outcomes.

Main Results:

• None of the patients (SIENA score 0-1) developed RVF (primary endpoint).
• A central venous pressure/pulmonary capillary wedge pressure (CVP/PCWP) ratio greater than 0.63 was significantly associated with adverse outcomes (mortality and rehospitalization) (ß = 2.99, p = 0.026).
• No other tested indices showed significant association with adverse outcomes.

Conclusions:

• Pre-implantation screening for RV dysfunction using the SIENA protocol effectively reduces the incidence of post-LVAD RVF.
• The CVP/PCWP ratio serves as a potential prognostic indicator for adverse events in patients with LVADs.
• Careful patient selection is paramount to minimize RVF risk following LVAD implantation.